APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nausea And Vomiting Treatment

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

Selected research

Market Analysis & Forecast

Global Nausea And Vomiting Treatment Market Analysis and Forecast 2026-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchNausea And Vomiting Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nausea And Vomiting Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nausea And Vomiting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nausea And Vomiting Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nausea And Vomiting Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.

United States is the largest Nausea And Vomiting Treatment market with about 42% market share. Europe is follower, accounting for about 20% market share.Merck & Co. Inc. was the global greatest company in Nausea And Vomiting Treatment industry, with the market Share of 14% , followed by Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro.

Report Includes

Read the full market overview

This report presents an overview of global market for Nausea And Vomiting Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nausea And Vomiting Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Nausea And Vomiting Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nausea And Vomiting Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nausea And Vomiting Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nausea And Vomiting Treatment revenue, projected growth trends, production technology, application and end-user industry.

Nausea And Vomiting Treatment Segment by Company

Merck & Co. Inc.

Helsinn Group

Unimed Pharmaceuticals (AbbVie Inc.)

Kyowa Kirin

Sanofi

Qilu Pharma

Teva Pharmaceutical Industries Ltd.

Taiji group

Novartis

Heron Therapeutics

Atnahs Pharma UK Limited

Mylan

Duchesnay

Tesaro

Nausea And Vomiting Treatment Segment by Type

Serotonin Receptor Antagonist

Neurokinin NK1 Receptor Antagonist

Others

Nausea And Vomiting Treatment Segment by Application

CINV

PONV

Motion Sickness

Pregnancy

Others

Nausea And Vomiting Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nausea And Vomiting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nausea And Vomiting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nausea And Vomiting Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nausea And Vomiting Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nausea And Vomiting Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nausea And Vomiting Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nausea And Vomiting Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Serotonin Receptor Antagonist Major Player Table 3. Neurokinin NK1 Receptor Antagonist Major Player Table 4. Others Major Player Table 5. Global Nausea And Vomiting Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. CINV Major Player Table 7. PONV Major Player Table 8. Motion Sickness Major Player Table 9. Pregnancy Major Player Table 10. Others Major Player Table 11. Nausea And Vomiting Treatment Industry Trends Table 12. Nausea And Vomiting Treatment Industry Drivers Table 13. Nausea And Vomiting Treatment Industry Opportunities and Challenges Table 14. Nausea And Vomiting Treatment Industry Restraints Table 15. Global Nausea And Vomiting Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nausea And Vomiting Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nausea And Vomiting Treatment Market Share by Region (2021-2026) Table 18. Global Nausea And Vomiting Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nausea And Vomiting Treatment Market Share by Region (2027-2032) Table 20. Global Nausea And Vomiting Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nausea And Vomiting Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Nausea And Vomiting Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nausea And Vomiting Treatment Key Players Headquarters & Area Served Table 24. Global Nausea And Vomiting Treatment Players, Product Type & Application Table 25. Global Nausea And Vomiting Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nausea And Vomiting Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nausea And Vomiting Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nausea And Vomiting Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Nausea And Vomiting Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Nausea And Vomiting Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nausea And Vomiting Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Nausea And Vomiting Treatment Revenue Market Share by Application (2027-2032) Table 38. Merck & Co. Inc. Company Information Table 39. Merck & Co. Inc. Business Overview Table 40. Merck & Co. Inc. Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Merck & Co. Inc. Nausea And Vomiting Treatment Product Portfolio Table 42. Merck & Co. Inc. Recent Development Table 43. Helsinn Group Company Information Table 44. Helsinn Group Business Overview Table 45. Helsinn Group Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Helsinn Group Nausea And Vomiting Treatment Product Portfolio Table 47. Helsinn Group Recent Development Table 48. Unimed Pharmaceuticals (AbbVie Inc.) Company Information Table 49. Unimed Pharmaceuticals (AbbVie Inc.) Business Overview Table 50. Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Product Portfolio Table 52. Unimed Pharmaceuticals (AbbVie Inc.) Recent Development Table 53. Kyowa Kirin Company Information Table 54. Kyowa Kirin Business Overview Table 55. Kyowa Kirin Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Kyowa Kirin Nausea And Vomiting Treatment Product Portfolio Table 57. Kyowa Kirin Recent Development Table 58. Sanofi Company Information Table 59. Sanofi Business Overview Table 60. Sanofi Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Sanofi Nausea And Vomiting Treatment Product Portfolio Table 62. Sanofi Recent Development Table 63. Qilu Pharma Company Information Table 64. Qilu Pharma Business Overview Table 65. Qilu Pharma Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Qilu Pharma Nausea And Vomiting Treatment Product Portfolio Table 67. Qilu Pharma Recent Development Table 68. Teva Pharmaceutical Industries Ltd. Company Information Table 69. Teva Pharmaceutical Industries Ltd. Business Overview Table 70. Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Product Portfolio Table 72. Teva Pharmaceutical Industries Ltd. Recent Development Table 73. Taiji group Company Information Table 74. Taiji group Business Overview Table 75. Taiji group Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Taiji group Nausea And Vomiting Treatment Product Portfolio Table 77. Taiji group Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Novartis Nausea And Vomiting Treatment Product Portfolio Table 82. Novartis Recent Development Table 83. Heron Therapeutics Company Information Table 84. Heron Therapeutics Business Overview Table 85. Heron Therapeutics Nausea And Vomiting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Heron Therapeutics Nausea And Vomiting Treatment Product Portfolio Table 87. Heron Therapeutics Recent Development Table 88. Atnahs Pharma UK Limited Company Information Table 89. Atnahs Pharma UK Limited Business Overview Table 90. Atnahs Pharma UK Limited Nausea And Vomiting Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Atnahs Pharma UK Limited Nausea And Vomiting Treatment Product Portfolio Table 92. Atnahs Pharma UK Limited Recent Development Table 93. Mylan Company Information Table 94. Mylan Business Overview Table 95. Mylan Nausea And Vomiting Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Mylan Nausea And Vomiting Treatment Product Portfolio Table 97. Mylan Recent Development Table 98. Duchesnay Company Information Table 99. Duchesnay Business Overview Table 100. Duchesnay Nausea And Vomiting Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Duchesnay Nausea And Vomiting Treatment Product Portfolio Table 102. Duchesnay Recent Development Table 103. Tesaro Company Information Table 104. Tesaro Business Overview Table 105. Tesaro Nausea And Vomiting Treatment Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Tesaro Nausea And Vomiting Treatment Product Portfolio Table 107. Tesaro Recent Development Table 108. North America Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America Nausea And Vomiting Treatment Revenue by Country (2021-2026) & (US$ Million) Table 114. North America Nausea And Vomiting Treatment Revenue by Country (US$ Million) & (2027-2032) Table 115. Europe Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Nausea And Vomiting Treatment Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Nausea And Vomiting Treatment Revenue by Country (US$ Million) & (2027-2032) Table 122. China Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 123. China Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 124. China Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 125. China Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 129. Asia Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Nausea And Vomiting Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Asia Nausea And Vomiting Treatment Revenue by Region (US$ Million) & (2021-2026) Table 132. Asia Nausea And Vomiting Treatment Revenue by Region (US$ Million) & (2027-2032) Table 133. SAMEA Nausea And Vomiting Treatment Revenue by Type (2021-2026) & (US$ Million) Table 134. SAMEA Nausea And Vomiting Treatment Revenue by Type (2027-2032) & (US$ Million) Table 135. SAMEA Nausea And Vomiting Treatment Revenue by Application (2021-2026) & (US$ Million) Table 136. SAMEA Nausea And Vomiting Treatment Revenue by Application (2027-2032) & (US$ Million) Table 137. SAMEA Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. SAMEA Nausea And Vomiting Treatment Revenue by Country (2021-2026) & (US$ Million) Table 139. SAMEA Nausea And Vomiting Treatment Revenue by Country (US$ Million) & (2027-2032) Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Nausea And Vomiting Treatment Image Figure 2. Global Nausea And Vomiting Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nausea And Vomiting Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Serotonin Receptor Antagonist Image Figure 5. Neurokinin NK1 Receptor Antagonist Image Figure 6. Others Image Figure 7. Global Nausea And Vomiting Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Nausea And Vomiting Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. CINV Image Figure 10. PONV Image Figure 11. Motion Sickness Image Figure 12. Pregnancy Image Figure 13. Others Image Figure 14. Global Nausea And Vomiting Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Nausea And Vomiting Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nausea And Vomiting Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nausea And Vomiting Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nausea And Vomiting Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nausea And Vomiting Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nausea And Vomiting Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Nausea And Vomiting Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nausea And Vomiting Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nausea And Vomiting Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Nausea And Vomiting Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nausea And Vomiting Treatment Revenue Share by Type (2021-2032) Figure 27. North America Nausea And Vomiting Treatment Revenue Share by Application (2021-2032) Figure 28. North America Nausea And Vomiting Treatment Revenue Share by Country (2021-2032) Figure 29. United States Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nausea And Vomiting Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nausea And Vomiting Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Nausea And Vomiting Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Nausea And Vomiting Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nausea And Vomiting Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nausea And Vomiting Treatment Revenue Share by Type (2021-2032) Figure 46. China Nausea And Vomiting Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Nausea And Vomiting Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nausea And Vomiting Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Nausea And Vomiting Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Nausea And Vomiting Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nausea And Vomiting Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nausea And Vomiting Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Nausea And Vomiting Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Nausea And Vomiting Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nausea And Vomiting Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Serotonin Receptor Antagonist
  • Neurokinin NK1 Receptor Antagonist
  • Others
Applications
  • CINV
  • PONV
  • Motion Sickness
  • Pregnancy
  • Others
Companies covered
  • Merck & Co. Inc.
  • Helsinn Group
  • Unimed Pharmaceuticals (AbbVie Inc.)
  • Kyowa Kirin
  • Sanofi
  • Qilu Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Taiji group
  • Novartis
  • Heron Therapeutics
  • Atnahs Pharma UK Limited
  • Mylan
  • Duchesnay
  • Tesaro

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nausea And Vomiting Treatment Market by Type
  3. 1.2.1 Global Nausea And Vomiting Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Serotonin Receptor Antagonist
  5. 1.2.3 Neurokinin NK1 Receptor Antagonist
  6. 1.2.4 Others
  7. 1.3 Nausea And Vomiting Treatment Market by Application
  8. 1.3.1 Global Nausea And Vomiting Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 CINV
  10. 1.3.3 PONV
  11. 1.3.4 Motion Sickness
  12. 1.3.5 Pregnancy
  13. 1.3.6 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nausea And Vomiting Treatment Market Dynamics
  1. 2.1 Nausea And Vomiting Treatment Industry Trends
  2. 2.2 Nausea And Vomiting Treatment Industry Drivers
  3. 2.3 Nausea And Vomiting Treatment Industry Opportunities and Challenges
  4. 2.4 Nausea And Vomiting Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nausea And Vomiting Treatment Market Perspective (2021-2032)
  2. 3.2 Global Nausea And Vomiting Treatment Growth Trends by Region
  3. 3.2.1 Global Nausea And Vomiting Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nausea And Vomiting Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Nausea And Vomiting Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nausea And Vomiting Treatment Revenue by Players
  2. 4.1.1 Global Nausea And Vomiting Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Nausea And Vomiting Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nausea And Vomiting Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nausea And Vomiting Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nausea And Vomiting Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Nausea And Vomiting Treatment Players, Product Type & Application
  8. 4.5 Global Nausea And Vomiting Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nausea And Vomiting Treatment Market CR5 and HHI
  11. 4.6.3 2025 Nausea And Vomiting Treatment Tier 1, Tier 2, and Tier 3
5 Nausea And Vomiting Treatment Market Size by Type
  1. 5.1 Global Nausea And Vomiting Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Nausea And Vomiting Treatment Revenue Market Share by Type (2021-2032)
6 Nausea And Vomiting Treatment Market Size by Application
  1. 6.1 Global Nausea And Vomiting Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Nausea And Vomiting Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck & Co. Inc.
  2. 7.1.1 Merck & Co. Inc. Company Information
  3. 7.1.2 Merck & Co. Inc. Business Overview
  4. 7.1.3 Merck & Co. Inc. Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck & Co. Inc. Nausea And Vomiting Treatment Product Portfolio
  6. 7.1.5 Merck & Co. Inc. Recent Developments
  7. 7.2 Helsinn Group
  8. 7.2.1 Helsinn Group Company Information
  9. 7.2.2 Helsinn Group Business Overview
  10. 7.2.3 Helsinn Group Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Helsinn Group Nausea And Vomiting Treatment Product Portfolio
  12. 7.2.5 Helsinn Group Recent Developments
  13. 7.3 Unimed Pharmaceuticals (AbbVie Inc.)
  14. 7.3.1 Unimed Pharmaceuticals (AbbVie Inc.) Company Information
  15. 7.3.2 Unimed Pharmaceuticals (AbbVie Inc.) Business Overview
  16. 7.3.3 Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Product Portfolio
  18. 7.3.5 Unimed Pharmaceuticals (AbbVie Inc.) Recent Developments
  19. 7.4 Kyowa Kirin
  20. 7.4.1 Kyowa Kirin Company Information
  21. 7.4.2 Kyowa Kirin Business Overview
  22. 7.4.3 Kyowa Kirin Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Kyowa Kirin Nausea And Vomiting Treatment Product Portfolio
  24. 7.4.5 Kyowa Kirin Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Nausea And Vomiting Treatment Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Qilu Pharma
  32. 7.6.1 Qilu Pharma Company Information
  33. 7.6.2 Qilu Pharma Business Overview
  34. 7.6.3 Qilu Pharma Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Qilu Pharma Nausea And Vomiting Treatment Product Portfolio
  36. 7.6.5 Qilu Pharma Recent Developments
  37. 7.7 Teva Pharmaceutical Industries Ltd.
  38. 7.7.1 Teva Pharmaceutical Industries Ltd. Company Information
  39. 7.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
  40. 7.7.3 Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Product Portfolio
  42. 7.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  43. 7.8 Taiji group
  44. 7.8.1 Taiji group Company Information
  45. 7.8.2 Taiji group Business Overview
  46. 7.8.3 Taiji group Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Taiji group Nausea And Vomiting Treatment Product Portfolio
  48. 7.8.5 Taiji group Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Nausea And Vomiting Treatment Product Portfolio
  54. 7.9.5 Novartis Recent Developments
  55. 7.10 Heron Therapeutics
  56. 7.10.1 Heron Therapeutics Company Information
  57. 7.10.2 Heron Therapeutics Business Overview
  58. 7.10.3 Heron Therapeutics Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Heron Therapeutics Nausea And Vomiting Treatment Product Portfolio
  60. 7.10.5 Heron Therapeutics Recent Developments
  61. 7.11 Atnahs Pharma UK Limited
  62. 7.11.1 Atnahs Pharma UK Limited Company Information
  63. 7.11.2 Atnahs Pharma UK Limited Business Overview
  64. 7.11.3 Atnahs Pharma UK Limited Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Atnahs Pharma UK Limited Nausea And Vomiting Treatment Product Portfolio
  66. 7.11.5 Atnahs Pharma UK Limited Recent Developments
  67. 7.12 Mylan
  68. 7.12.1 Mylan Company Information
  69. 7.12.2 Mylan Business Overview
  70. 7.12.3 Mylan Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Mylan Nausea And Vomiting Treatment Product Portfolio
  72. 7.12.5 Mylan Recent Developments
  73. 7.13 Duchesnay
  74. 7.13.1 Duchesnay Company Information
  75. 7.13.2 Duchesnay Business Overview
  76. 7.13.3 Duchesnay Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Duchesnay Nausea And Vomiting Treatment Product Portfolio
  78. 7.13.5 Duchesnay Recent Developments
  79. 7.14 Tesaro
  80. 7.14.1 Tesaro Company Information
  81. 7.14.2 Tesaro Business Overview
  82. 7.14.3 Tesaro Nausea And Vomiting Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Tesaro Nausea And Vomiting Treatment Product Portfolio
  84. 7.14.5 Tesaro Recent Developments
8 North America
  1. 8.1 North America Nausea And Vomiting Treatment Revenue (2021-2032)
  2. 8.2 North America Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Nausea And Vomiting Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Nausea And Vomiting Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Nausea And Vomiting Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Nausea And Vomiting Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Nausea And Vomiting Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Nausea And Vomiting Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Nausea And Vomiting Treatment Revenue by Country
  11. 8.6.1 North America Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nausea And Vomiting Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Nausea And Vomiting Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Nausea And Vomiting Treatment Revenue (2021-2032)
  2. 9.2 Europe Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nausea And Vomiting Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nausea And Vomiting Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Nausea And Vomiting Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nausea And Vomiting Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nausea And Vomiting Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Nausea And Vomiting Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nausea And Vomiting Treatment Revenue by Country
  11. 9.6.1 Europe Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nausea And Vomiting Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nausea And Vomiting Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Nausea And Vomiting Treatment Revenue (2021-2032)
  2. 10.2 China Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Nausea And Vomiting Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Nausea And Vomiting Treatment Revenue by Type (2027-2032)
  5. 10.3 China Nausea And Vomiting Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Nausea And Vomiting Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Nausea And Vomiting Treatment Revenue by Application (2027-2032)
  9. 10.5 China Nausea And Vomiting Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nausea And Vomiting Treatment Revenue (2021-2032)
  2. 11.2 Asia Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nausea And Vomiting Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nausea And Vomiting Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Nausea And Vomiting Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nausea And Vomiting Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nausea And Vomiting Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Nausea And Vomiting Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nausea And Vomiting Treatment Revenue by Country
  11. 11.6.1 Asia Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nausea And Vomiting Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nausea And Vomiting Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nausea And Vomiting Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Nausea And Vomiting Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nausea And Vomiting Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nausea And Vomiting Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nausea And Vomiting Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nausea And Vomiting Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nausea And Vomiting Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nausea And Vomiting Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nausea And Vomiting Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nausea And Vomiting Treatment Revenue by Country
  11. 12.6.1 SAMEA Nausea And Vomiting Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nausea And Vomiting Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nausea And Vomiting Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst